In glioma patients, TAM BMDM invade the tumor core displaying an anti-inflammatory and pro-angiogenic phenotype, expressing immunosuppressive cytokines (i.e. Il10 and Tgfβ2) and markers of active phagocytosis (CD93). The gene discussed is IL10; the disease is glioma.